Imiquimod and Tumor Lysate Vaccine Immunotherapy in Adults With High Risk or Recurrent Grade II Gliomas
Status:
Completed
Trial end date:
2018-11-08
Target enrollment:
Participant gender:
Summary
This is a pilot study of a vaccination regime that is designed to efficiently induce
anti-tumor T-cell responses in patients with WHO grade II glioma. The proposed regime with
BTIC Lysate in combination with imiquimod, an FDA-approved immune response modifier will
induce potent anti-glioma immune response with minimal or no toxicity.
Phase:
Early Phase 1
Details
Lead Sponsor:
Frank Lieberman University of Pittsburgh
Collaborators:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute